Insider Transactions in Q4 2020 at Surface Oncology, Inc. (SURF)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2020
|
David S. Grayzel Director |
SELL
Open market or private sale
|
Indirect |
1,700,000
-36.59%
|
$30,600,000
$18.1 P/Share
|
|
Dec 17
2020
|
Atlas Venture Fund Ix, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,700,000
-36.59%
|
$30,600,000
$18.1 P/Share
|
|
Dec 15
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-1.01%
|
$10,000
$10.48 P/Share
|
|
Dec 11
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,405
-1.4%
|
$14,050
$10.05 P/Share
|
|
Nov 25
2020
|
Jessica Fees Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,383
+0.34%
|
$5,532
$4.52 P/Share
|
|
Nov 11
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
595
-0.59%
|
$5,950
$10.05 P/Share
|
|
Oct 28
2020
|
Jessica Fees Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,895
+2.32%
|
$19,580
$4.21 P/Share
|
|
Oct 14
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.81%
|
$40,000
$10.05 P/Share
|